Health Canada is informing Canadians of an ongoing safety review of the potential association between the diabetes drug Lantus (insulin glargine) and an increased risk of developing cancer.
This is a summary of a recall issued by Health Canada. The link below will take you to the original recall press release containing complete information, including instructions about what to do if you are affected by this recall.
View Full Details Of Original Health Canada Recall Notice Here.
